IL-23IL-23

Back to Disease

October 2025

Medication Review: What Is the Evidence For Guselkumab Efficacy In Inhibiting The Progression of Structural Damage?

October 2025

FAQ: What is the Effect of Guselkumab on Structural Damage in PsA?

March 2025

Long-Term Guselkumab Safety in Psoriasis & PsA (Phase II/III Analysis)

May 2025

What is the Real World Evidence of Guselkumab in PsA

November 2024

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

April 2025

What is the Efficacy of Guselkumab Across the GRAPPA Domains?

September 2024

Data Review From the Phase III DISCOVER-2 Trials

July 2024

Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

December 2024

What Is the Safety Profile of Guselkumab in PsO and PsA?

March 2025

How do IL-23 and IL-17 Inhibitors Differ in Clinical Efficacy

sectionimg

dotsimg

Download the app and start using it now.

Download on the App Store

GET IT ON Google Play